141 related articles for article (PubMed ID: 25009296)
1. T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness.
Pinto F; Pértega-Gomes N; Pereira MS; Vizcaíno JR; Monteiro P; Henrique RM; Baltazar F; Andrade RP; Reis RM
Clin Cancer Res; 2014 Sep; 20(18):4949-61. PubMed ID: 25009296
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody.
Hamilton DH; Fernando RI; Schlom J; Palena C
Oncotarget; 2015 Mar; 6(7):4853-62. PubMed ID: 25605015
[TBL] [Abstract][Full Text] [Related]
3. Expression of Brachyury gene is a significant prognostic factor for primary lung carcinoma.
Haro A; Yano T; Kohno M; Yoshida T; Koga T; Okamoto T; Takenoyama M; Maehara Y
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S509-16. PubMed ID: 23456319
[TBL] [Abstract][Full Text] [Related]
4. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy.
Palena C; Polev DE; Tsang KY; Fernando RI; Litzinger M; Krukovskaya LL; Baranova AV; Kozlov AP; Schlom J
Clin Cancer Res; 2007 Apr; 13(8):2471-8. PubMed ID: 17438107
[TBL] [Abstract][Full Text] [Related]
5. Brachyury oncogene is a prognostic factor in high-risk testicular germ cell tumors.
Pinto F; Cárcano FM; da Silva ECA; Vidal DO; Scapulatempo-Neto C; Lopes LF; Reis RM
Andrology; 2018 Jul; 6(4):597-604. PubMed ID: 29749711
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer: Brachyury--a biomarker for progression and prognosis?
Thoma C
Nat Rev Urol; 2014 Sep; 11(9):485. PubMed ID: 25069730
[No Abstract] [Full Text] [Related]
7. Expression of brachyury in hemangioblastoma: potential use in differential diagnosis.
Barresi V; Vitarelli E; Branca G; Antonelli M; Giangaspero F; Barresi G
Am J Surg Pathol; 2012 Jul; 36(7):1052-7. PubMed ID: 22446946
[TBL] [Abstract][Full Text] [Related]
8. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
Rehman I; Azzouzi AR; Cross SS; Deloulme JC; Catto JW; Wylde N; Larre S; Champigneuille J; Hamdy FC
Hum Pathol; 2004 Nov; 35(11):1385-91. PubMed ID: 15668896
[TBL] [Abstract][Full Text] [Related]
9. Expression of epithelial-mesenchymal transition driver brachyury and status of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in predicting treatment responses to neoadjuvant chemotherapy of breast cancer.
Lee KH; Kim EY; Park YL; Do SI; Chae SW; Park CH
Tumour Biol; 2017 Jun; 39(6):1010428317710575. PubMed ID: 28621227
[TBL] [Abstract][Full Text] [Related]
10. KITENIN is associated with tumor progression in human gastric cancer.
Ryu HS; Park YL; Park SJ; Lee JH; Cho SB; Lee WS; Chung IJ; Kim KK; Lee KH; Kweon SS; Joo YE
Anticancer Res; 2010 Sep; 30(9):3479-86. PubMed ID: 20944126
[TBL] [Abstract][Full Text] [Related]
11. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
12. The embryonic Brachyury transcription factor is a novel biomarker of GIST aggressiveness and poor survival.
Pinto F; Campanella NC; Abrahão-Machado LF; Scapulatempo-Neto C; de Oliveira AT; Brito MJ; Andrade RP; Guimarães DP; Reis RM
Gastric Cancer; 2016 Apr; 19(2):651-659. PubMed ID: 25995035
[TBL] [Abstract][Full Text] [Related]
13. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
14. Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases.
Miettinen M; Wang Z; Lasota J; Heery C; Schlom J; Palena C
Am J Surg Pathol; 2015 Oct; 39(10):1305-12. PubMed ID: 26099010
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy.
Li T; Huang S; Dong M; Gui Y; Wu D
Urol Oncol; 2013 Nov; 31(8):1539-45. PubMed ID: 23089540
[TBL] [Abstract][Full Text] [Related]
16. Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer.
Pinto F; Pértega-Gomes N; Vizcaíno JR; Andrade RP; Cárcano FM; Reis RM
Oncotarget; 2016 May; 7(20):28891-902. PubMed ID: 27049720
[TBL] [Abstract][Full Text] [Related]
17. The T-box transcription factor brachyury behaves as a tumor suppressor in gliomas.
Pinto F; Costa ÂM; Santos GC; Matsushita MM; Costa S; Silva VA; Miranda-Gonçalves V; Lopes CM; Clara CA; Becker AP; Neder L; Hajj GN; da Cunha IW; Jones C; Andrade RP; Reis RM
J Pathol; 2020 May; 251(1):87-99. PubMed ID: 32154590
[TBL] [Abstract][Full Text] [Related]
18. Chordoma: Immunohistochemical Analysis of Brachury.
Sun HI; Guduk M; Gucyetmez B; Yapicier O; Pamir MN
Turk Neurosurg; 2018; 28(2):174-178. PubMed ID: 28094431
[TBL] [Abstract][Full Text] [Related]
19. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
[TBL] [Abstract][Full Text] [Related]
20. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
